Survival in patients with non - small cell lung cancer vaccinated with CIMAvax-EGF

Authors

  • Carlos Oliver Cobián Caballero Hospital Provincial Docente Clinicoquirúrgico “Saturnino Lora Torres”, Universidad de Ciencias Médicas, Santiago de Cuba
  • Soraida Cándida Acosta Brooks Hospital Provincial Docente Clinicoquirúrgico “Saturnino Lora Torres”, Universidad de Ciencias Médicas, Santiago de Cuba
  • Francisco Martínez Feria Hospital General "Juan Bruno Zayas A."
  • Lázaro Ibrahim Romero García Hospital Provincial Docente Clinicoquirúrgico “Saturnino Lora Torres”, Universidad de Ciencias Médicas, Santiago de Cuba

Keywords:

global survival, non - small cell lung cancer, cancer vaccine, CIMAvax-EGF.

Abstract

An observational, descriptive and cross-sectional study in a first moment, and cohort analytic in a second time, of 95 patients with  non - small cell lung cancer in advanced stages, assisted at “Saturnino Lora Torres” Teaching Clinical Surgical Provincial Hospital  and in 4 polyclinics of  Santiago de Cuba, was carried out during the period 2006-2013, in order to estimate the survival in them after the vaccination with CIMAvax-EGF and to identify the factors associated to the mortality, for which Kaplan-Meier method and Cox regression were used, respectively.  The global survival in 2 years was 20.7%, with a median of 13 months, as long as the survival a year after applying the vaccine was 36.5%.  On the other hand, in the stage IIIB, the favorable response to the first line treatment, the chemotherapy-radiotherapy-vaccine combination and the immunization in 4 or more occasions, facilitated a significantly higher survival.  The unfavorable reaction to the first therapeutic line constituted a prediction factor of death risk increase in the population affected.

Downloads

Download data is not yet available.

References

1. Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Harrison’s Principles of Internal Medicine. 18 ed. New York: McGraw-Hill Education; 2011.

2. Castelao JN, Fernández JF. Manual CTO de Medicina y Cirugía (Neumología y Cirugía Torácica). 8 ed. Madrid: CTO Editorial; 2011.

3. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, et al. Non-small-cell lung cancer. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2010; 8(7): 740-801.

4. Goldman L, Schafer A, Arend W, Armitage J, Clemmons D, Drazen J, et al. Goldman’s Cecil Medicine. 24 ed. Philadelphia: Elsevier Saunders; 2012.

5. Schiller JH, Gandara DR, Gloss GD, Vokes EE. Non–small-cell lung cancer: then and now. J Clin Oncol. 2013; 31(8): 981-3.

6. Abreu Rivera P, Labrada Betancourt Y, Sánchez Escalona JL, Alvares Zaldívar J. Evaluación de supervivencia de pacientes con cáncer de pulmón tratados con la vacuna de factor de crecimiento epidérmico. Corr Cient Méd Holg. 2011 [citado 23 Jul 2014]; 15(1). Disponible en: http://www.cocmed.sld.cu/no151/no151ori08.htm

7. Acosta SC. Ensayo Clínico Fase III: Vacuna terapéutica CIMAvax EGF combinada con la quimioterapia adyuvante en pacientes con tumores resecables de pulmón de células no pequeñas. La Habana: Centro de Inmunología Molecular; 2011.

8. García Verdecia B. Estudio de la respuesta inmune humoral inducida con la vacuna CIMAvax-EGF y de su relación con la supervivencia de pacientes con cáncer de pulmón de células no pequeñas [tesis doctoral]. La Habana: Universidad de La Habana; 2011 [citado 13 Mar 2014]. Disponible en: http://tesis.repo.sld.cu/412/1/BGarciaVerdecia.pdf

9. Cotran R, Kumar V, Collin T. Robins: Patología estructural y funcional. 7 ed. Madrid: McGraw-Hill Interamericana; 2008.

10. Cooper DH, Krainik AJ, Lubner SJ, Reno HL. The Washington Manual of Medical Therapeutics. 32 ed. Saint Louis: Lippincott Williams & Wilkins; 2007.

11. Cortés-Funes H, Colomer R, Alba E, Díaz-Rubio E, González M, Guillem V, et al. Tratado de oncología. Barcelona: Publicaciones Permanyer; 2009.

12. Lage Dávila A, Crombet Ramos T. Control del cáncer avanzado: La ruta hacia la cronicidad. Anales de la Academia. 2011 [citado 16 Abr 2014]; 1(1). Disponible en: http://www.revistaccuba.cu/index.php/acc/article/viewFile/71/58

13. Díaz A, Lage A. Terapias con inhibidores del receptor del factor de crecimiento epidérmico: acercando el futuro. Biotecnología Aplicada. 2007 [citado 16 Abr 2014]; 24(1). Disponible en: http://132.248.9.34/hevila/Biotecnologiaaplicada/2007/vol24/no1/1.pdf

14. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362(25): 2380-8.

15. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008; 358(11): 1160-74.

16. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non–small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011; 29(1): 2866-74.

17. Acosta Brooks SC. Posicionamiento de CIMAvax-EGF en la terapéutica del cáncer de pulmón no células pequeñas. III Meeting de CIMAvax–EGF. La Habana: Centro de Inmunología Molecular; 2010.

Downloads

Published

2016-02-29

How to Cite

1.
Cobián Caballero CO, Acosta Brooks SC, Martínez Feria F, Romero García LI. Survival in patients with non - small cell lung cancer vaccinated with CIMAvax-EGF. MEDISAN [Internet]. 2016 Feb. 29 [cited 2025 Jun. 3];20(3). Available from: https://medisan.sld.cu/index.php/san/article/view/737

Issue

Vol. 20 No. 3 (2016): MEDISAN

Section

Original Articles

License

All the articles can be downloaded or read for free. The journal does not charge any amount of money to the authors for the reception, edition or the publication of the articles, making the whole process completely free. Medisan has no embargo period and it is published under the license of Creative Commons, International Non Commercial Recognition 4.0, which authorizes the copy, reproduction and the total or partial distribution of the articles in any format or platform, with the conditions of citing the source of information and not to be used for profitable purposes.